Update 2024: Psychedelic Pharmacy - New Frontiers in Psychiatry

Presenter

Jagpaul Kaur Deol
BSc(Pharm), RPh

Jagpaul has served as an Assistant Professor of Teaching at UBC Faculty of Pharmaceutical Sciences and currently guest lectures at UBC, VIU, UofT, UC Berkley and others. She works as a pharmacist in specialized community care and multidisciplinary medical clinics focusing on her specialties in HIV+infectious diseases and mental health+addictions. She has over a decade of experience in psychedelic and cannabinoid medicine through harm reduction. She is currently completing her Master’s Degree in Applied Neuroscience (Psychiatry) with a focus on Psychedelic-assisted Therapy and is a co-investigator on several upcoming Health Canada approved clinical trials with psilocybin and MDMA. She is the pharmacotherapy educational lead for several accredited Psychedelic-assisted Therapy training programs for Physicians, Nurse Practitioners, Psychologists, and Psychotherapists.

Session Information

Description

The emergence of Psychedelic-assisted Therapy (PAT) as a new treatment paradigm for Canadians experiencing end-of-life distress, treatment-resistant depression, and PTSD requires understanding of both safety and efficacy. This session delivers an essential primer on PAT, focussing on psilocybin and MDMA. Through a brief discussion of current clinical research, participants will receive an overview of PAT neuroscience and pharmacotherapy. Review of the current regulatory landscape of PAT in Canada will lead to the emerging role of psychiatric pharmacists in PAT medication management.

Learning Objectives

1. Discuss the general principles of Psychedelic-assisted Therapy.
2. Describe the main mechanisms of action of psilocybin and MDMA.
3. Outline the various Health Canada approved access routes for patients seeking psilocybin and MDMA.
4. List safety concerns of psilocybin and MDMA that can be minimized with pharmacist involvement.